Tumor targeted drug delivery system has been developed as a promising approach to improve cancer chemotherapy. The design of hyaluronic acid (HA)-modified nanocarriers has been proven to be effective for targeting CD44 overexpressing tumor cells. Moreover, combination therapy can improve the therapeutic effect and delay the development of drug resistance. In this study, doxorubicin (DOX) and paclitaxel
肿瘤靶向药物递送系统已经被开发为改善癌症
化学疗法的有前途的方法。透明质酸(HA)修饰的纳米载体的设计已被证明可有效靶向C
D44过表达的肿瘤细胞。此外,联合疗法可改善治疗效果并延缓耐药性的发展。在这项研究中,通过插入后方法制备了用酸可裂解的
胆固醇-HA缀合物(Chol-HA)修饰的
阿霉素(DOX)和
紫杉醇(
PTX)共载脂质体递送系统。双药共载HA修饰脂质体(HA-D / P-Lip)的合适粒径为125.5±0.79 nm,负表面电荷为-9.56±0.62 mV,可接受的包封效率为93.6±0.51% (DOX)和70.4±1.46%(
PTX)。体外药物释放研究表明,在pH 5.5
磷酸盐缓冲液中,两种药物在72 h内的累积释放量远高于pH 7.4
磷酸盐缓冲液。通过M
TT分析,与游离药物或单一药物负载脂质体相比,针对MCF-7乳腺癌细胞的体外细胞毒性研究显示出优异的细胞毒性和明显的协同作用。体外